Frankfurter Institut Fuer Klinische Krebsforschung IKF
Frankfurter Institut Fuer Klinische Krebsforschung IKF is recorded as a service provider in 9 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 9 of 9 trials · Latest update first
ACO/ARO/AIO-18.2 Preoperative FOLFOX versus postoperative risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure: A randomized phase III trial of the German Rectal Cancer Study Group
Sponsor Heidelberg University
- Start (EU)
- Latest update
- Estimated end
- Not reported
Short course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined intermediate and high-risk rectal cancer patients, A randomized phase III trial of the German Rectal Cancer Study Group
Sponsor Goethe University Frankfurt
- Start (EU)
- Latest update
- Estimated end
ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus trifluridine/tipiracil alone for metastatic oeso-gastric adenocarcinoma.
Sponsor Fondation Franc.Cancerologie Digestive
- Start (EU)
- Latest update
- Estimated end
- Not reported
An open labelled phase III adjuvant trial of disease-free survival in patients with resected pancreatic ductal adenocarcinoma randomized to allocation of oxaliplatin- or gemcitabine-based chemotherapy by standard clinical criteria or by a transcriptomic treatment specific stratification signature (ESPAC-6)
Sponsor Universitaetsklinikum Heidelberg AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
Sequential or up-front triple treatment with durvalumab, tremelimumab and bevacizumab for non-resectable hepatocellular carcinoma (HCC) patients (MONTBLANC)
Sponsor Klinikum der Universitaet Muenchen AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
Post-resection/ ablation chemotherapy in patients with metastatic colorectal cancer (FIRE-9 - PORT / AIO-KRK-0418). Prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of active post-resection/ ablation therapy in patients with metastatic colorectal cancer.
Sponsor Charite Universitaetsmedizin Berlin KöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
Osimertinib plus chemotherapy as 1st line therapy in stage IV NSCLC patients with atypical EGFR mutations (AIO-TRK/YMO-0324)
Sponsor Universitat Heidelberg
- Start (EU)
- Latest update
- Estimated end
- Not reported
A randomized, 2-arm non-comparative phase II study on the efficacy of atezolizumab and Roche bevacizumab (Atezo/Bev) followed by on-demand selective TACE (sdTACE) upon detection of disease progression or of initial synchronous treatment with TACE and Atezo/Bev on objective response rate in the treatment of unresectable hepatocellular carcinoma patients (DEMAND)
Sponsor Klinikum der Universitaet Muenchen AöR
- Start (EU)
- Latest update
- Estimated end
- Not reported
A First-In-Human, phase I/IIa, open-label trial assessing safety, tolerability, and feasibility of repeated administrations of a novel autologous tumor-infiltrating lymphocyte-based immunotherapy in patients with metastatic colorectal or prostate cancer
Sponsor CuraCell Holding AB
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Frankfurter Institut Fuer Klinische Krebsforschung IKF?
The 2026-10-09 snapshot links Frankfurter Institut Fuer Klinische Krebsforschung IKF to 9 distinct CTIS trials. Recorded services include Clinical monitoring, Data management, Project management, Electronic data capture, among 11 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Frankfurter Institut Fuer Klinische Krebsforschung IKF?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Gastroenterology, Hepatology. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Frankfurter Institut Fuer Klinische Krebsforschung IKF conducted?
The linked trials record locations in 5 countries, including Germany, Spain, France, Italy, Sweden. These are trial locations, not confirmed office locations or countries where Frankfurter Institut Fuer Klinische Krebsforschung IKF delivered services.
What can this page tell me about Frankfurter Institut Fuer Klinische Krebsforschung IKF's trial experience?
Browse 9 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Frankfurter Institut Fuer Klinische Krebsforschung IKF. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH